Apnimed Inc (APMD) Stock Analysis
Verdict: WATCH (do not buy)
AD109's Feb 28, 2027 PDUFA date offers major upside, but binary FDA approval risk and post-IPO momentum loss justify patience.
Investment score: 55/100
Analysis as of
Is Apnimed Inc stock worth reviewing? The TradeMates thesis
TradeMates assigns APMD an Investment Score of 55/100 (Watch). While the FDA acceptance of AD109's NDA with a PDUFA date of Feb 28, 2027 and a $220.8M capital raise secure runway, heavy post-IPO technical selling (-30.9% in 30 days) warrants awaiting clear technical consolidation.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 65/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Apnimed Inc opportunities and risks
What speaks for APMD
- FDA NDA Acceptance for lead drug AD109 with PDUFA date set for Feb 28, 2027
What speaks against APMD
- Binary FDA regulatory approval risk on lead asset AD109
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.3% |
| ALMS | n/a | 119.0x | n/a | 88.2% | -5933.5% | -40.0% |
| ANRO | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.8% |
| COLL | 15.5x | 1.0x | 3.2x | 60.0% | 5.9% | 42.6% |
| LXRX | n/a | 16.4x | n/a | 98.9% | -147.4% | -11.7% |
| Peer median | n/a | 1.0x | n/a | 60.0% | 0.0% | -7.8% |
Frequently asked questions about Apnimed Inc (APMD)
Is APMD stock a good investment?
The TradeMates model rates Apnimed Inc as WATCH (do not buy) with an investment score of 55/100. TradeMates assigns APMD an Investment Score of 55/100 (Watch). While the FDA acceptance of AD109's NDA with a PDUFA date of Feb 28, 2027 and a $220.8M capital raise secure runway, heavy post-IPO technical selling (-30.9% in 30 days) warrants awaiting clear technical consolidation. This is algorithmic model output, not personal investment advice.
Is APMD stock a buy?
The TradeMates model verdict for APMD is WATCH (do not buy) with an investment score of 55/100. Treat this as a model signal to review, not a personal buy recommendation.